Hold Lupin With Stop Loss Of Rs 425
Technical analyst PK Agarwal of Purpleline Investment has maintained 'hold' rating on Lupin Limited stock with medium-to-long term view.
According to analyst, the investors can buy the stock with a stop loss of Rs 425.
Today, the stock of the company opened at Rs 468 on the Bombay Stock Exchange (BSE).
The share price has seen a 52-week high of Rs 519.80 and a low of Rs 277 on BSE.
Current EPS & P/E ratio stood at 17.78 and 25.48 respectively.
Lupin on Nov 02 declared that its US arm, Lupin Pharmaceuticals (LPI), has been given final nod for Suprax (Cefixime) Chewable Tabs from USFDA.
The company bagged the nod to make and sell the drug in the potencies of 100 mg, 150 mg and 200 mg.
Moreover, the company has recorded an increase of 34.14% in its consolidated net profit for the three month period ended Sep 2010.
During the same period, the company's consolidated net profit remained at Rs 2150.2 million for the period under review as compared to Rs 1,603 million in the same quarter of last year.